Medication Discovery Using Rat Models of Relapse

Closed Solicitation Posted

This opportunity was awarded. See the award notice from .

Solicitation number
75N95024R00011
Agency
National Institute on Drug Abuse National Institutes of Health, Department of Health and Human Services
Responses due
Set-aside
No set-aside

Opportunity facts

NAICS code
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Place of performance
Rockville, Maryland, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The National Institute on Drug Abuse intends to award a cost-reimbursement contract to identify and test novel compounds for their efficacy in established rodent models of relapse for cocaine, nicotine, methamphetamine, or opioid drug addiction. Offerors must possess the necessary DEA registrations and demonstrate compliance with animal research requirements to handle controlled substances and conduct these studies. Proposals are due April 1, 2024 and the agency anticipates making an award by July 2024 with an initial one-year base period and four one-year options. The contract objectives are to determine compounds' ability to block stress-, drug- or cue-induced reinstatement of drug-seeking behaviors following extinction training using standard self-administration procedures.

This solicitation has no set-aside designation. The primary NAICS code is 541715 for research and development in the social sciences and humanities, with work expected to take place in Rockville, Maryland. Mandatory qualifications include DEA registration for schedules I through V controlled substances. The contractor must report out study findings and identify promising candidates for follow-up evaluation.

Notice text

The National Institute on Drug Abuse (NIDA) intends to solicit proposals from qualified organizations (NAICS Code 541715) having in-house capability to develop methodologies and to perform in vivo rodent behavioral pharmacology for other drug dependence disorders, using drug self-administration reinstatement models.

The object of this contract is to determine the in vivo efficacy of novel compounds in animal models of relapse using cocaine, nicotine, methamphetamine, or opioids. This includes the following tests in animals trained to self-administer cocaine (for example): (1) the ability of test compound to block footshock or other stress-induced reinstatement of responding after a period of experimental extinction; (2) the ability of a test compound to block priming-induced reinstatement of responding after a period of extinction; and (3) the ability of a test compound to block the effects of a conditioned cue (previously paired with the training drug) to reinstate responding for the training drug (cocaine, nicotine, methamphetamine, or an opioid) after a period of extinction.

An integral part of this work is to develop methods and to design and implement protocols for the evaluation of test compounds. A number of laboratories have used some of the methodologies described in the literature. While recognizing the need for methods development, NIDA anticipates that by Option Period 1, if Options are exercised, the majority of the Contractor’s efforts will be devoted to test compound evaluations. The Contractor shall identify and acquire standard compounds that merit the aforementioned types of evaluation. In addition, if NIDA exercises specific contract options, this contract shall support follow-up rodent pharmacology studies of compounds identified as promising potential drug-dependence treatment agents including through the use of drug selfadministration studies. The details of these latter studies cannot be specified before contract award; they will depend upon specific successes in NIDA’s medication discovery efforts and scientific advances in the general field of drug abuse research. Written reports documenting the study findings are the anticipated end products of this contract.

Mandatory Criteria:

Due to the nature of the compounds which will be evaluated under this contract, it is mandatory that offerors possess prior to award US Department of Justice Drug Enforcement Administration (DEA) Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970. In addition, the successful offeror must either possess or demonstrate the ability to obtain prior to award DEA registration for Schedule I controlled substances.

The offeror must demonstrate its understanding and compliance with the NIH Guide for Care and Use of Laboratory Animals. The Offeror shall submit evidence that its proposal was reviewed and approved by the Institution’s Animal Care and Use Committee (IACUC). The Assurance number shall be provided with the proposal.

Notice:

We anticipate the award of one cost-reimbursement, level of effort contract for a base period of one year with four one-year options to extend performance. The contract will include additional quantity options.

RFP No. 75N95024R00011 will be available electronically on or about 45 days from the date of this posting. You can access the RFP through the sam.gov (URL: http://sam.gov) or through the NIDA website: (URL:http://www.drugabuse.gov/funding/funding-opportunities/nida-requestscontract-proposals-rfps ). All information required for the submission of a proposal will be contained in or accessible through the RFP package.

Responses to the RFP will be due 45 days from the release date. NIDA anticipates a July 2024 award date. NIDA will consider proposals submitted by any responsible offeror.

Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government’s requirement with a commercial item within 15 days of this notice.

This advertisement does not commit the Government to award a contract.

For more details please see the attached RFP.

Attachments

Files attached to this notice, newest first
File Type Posted
RFP Ammendment 1.pdf PDF
RFP 75N95024R00011 (002).pdf PDF

Notice history

Notices posted for this opportunity, newest first
Notice Type Posted
Medication Discovery Using Rat Models of Relapse Award Award Notice
Medication Discovery Using Rat Models of Relapse This notice · Latest solicitation Solicitation
Medication Discovery Using Rat Models of Relapse Pre-Solicitation
Medication Discovery Using Rat Models of Relapse Original Pre-Solicitation

On GovTribe

Work this opportunity on GovTribe

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity